Publications by authors named "Celia P Jenkinson"
Unlabelled: Sparsentan, a dual endothelin receptor A inhibitor and angiotensin blocker, reduced proteinuria in patients with focal segmental glomerulosclerosis (FSGS) in Phase II and Phase III studies. However, the estimated glomerular filtration rate (eGFR) endpoint was not achieved, partially attributed to disease heterogeneity among participants. Sparsentan reversed the molecular fingerprint in kidneys of an adriamycin-challenged rat model of chronic kidney disease, consistent with the phenotypic data.
View Article and Find Full Text PDFArticle Synopsis
- IgA nephropathy (IgAN) involves kidney damage caused by immune complexes formed from a specific type of IgA that has unusual glycan structures, leading to complications like kidney failure in many patients.
- To study this condition, researchers created a model using engineered immune complexes in mice to mimic IgAN and examined the effects of sparsentan, a drug that targets certain receptors in the body.
- The results showed that sparsentan reduced kidney cell overgrowth and inflammation, suggesting it could help protect against kidney damage from IgAN, indicating potential for human treatment insights.
Background: NASH causes a tremendous health care burden in the United States. A glucagon-like peptide-1 agonist, semaglutide (Sema), treatment resulted in hepatic steatosis reduction in clinical trials of NASH. Lysophosphatidic acid receptor 1 antagonists are known to have antifibrotic effects in several organs.
View Article and Find Full Text PDF